CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancerMalachi Griffith, Obi L. Griffith, Nicholas C. Spies et al.|Nature Genetics|2017Cited by 673
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen PredictionDaniel K. Wells, Elham Sherafat, Marit M. van Buuren et al.|Cell|2020Cited by 534
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S. Grasso, Antoni Ribas, Jennifer Tsoi et al.|Cancer Cell|2020Cited by 379
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Katie M. Campbell et al.|Clinical Cancer Research|2020Cited by 368
Non-viral precision T cell receptor replacement for personalized cell therapySusan P. Foy, James R. Heath, Stefanie Mandl et al.|Nature|2022Cited by 276